Probiotec Ltd
ASX:PBP

Watchlist Manager
Probiotec Ltd Logo
Probiotec Ltd
ASX:PBP
Watchlist
Price: 2.98 AUD Market Closed
Market Cap: 242.3m AUD
Have any thoughts about
Probiotec Ltd?
Write Note

Probiotec Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Probiotec Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Probiotec Ltd
ASX:PBP
Interest Income Expense
-AU$6m
CAGR 3-Years
-40%
CAGR 5-Years
-37%
CAGR 10-Years
-15%
Mayne Pharma Group Ltd
ASX:MYX
Interest Income Expense
AU$679k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Interest Income Expense
AU$1.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Botanix Pharmaceuticals Ltd
ASX:BOT
Interest Income Expense
AU$46.6k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vita Life Sciences Ltd
ASX:VLS
Interest Income Expense
AU$754k
CAGR 3-Years
166%
CAGR 5-Years
19%
CAGR 10-Years
54%
Arovella Therapeutics Ltd
ASX:ALA
Interest Income Expense
-AU$8.6k
CAGR 3-Years
36%
CAGR 5-Years
41%
CAGR 10-Years
N/A
No Stocks Found

Probiotec Ltd
Glance View

Market Cap
242.3m AUD
Industry
Pharmaceuticals

Probiotec Ltd. engages in manufacture, market and distribution of over-the-counter pharmaceuticals, complementary medicines and specialty ingredients. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-11-14. The firm owns approximately six manufacturing facilities in Australia and distributes its products both domestically and internationally. The Company’s products are manufactured on behalf of a range of clients, including international companies. The company also owns Multipack-LJM business, a contract packer, providing packing services for a range of pharmaceutical, consumer healthcare, cosmetics and food, and beverage companies. The firm subsidiaries include Probiotec Pharmaceuticals Pty Ltd, Probiotec Pharma Pty Ltd, Biotech Pharmaceuticals Australia Pty Ltd, Biotech Pharmaceuticals Pty Ltd, Probiotec (NSW) Pty Ltd, Australian Dairy Proteins Pty Ltd, Milton Pharmaceuticals Pty Ltd and Willie Labs Generics Pty Ltd.

PBP Intrinsic Value
3.96 AUD
Undervaluation 25%
Intrinsic Value
Price

See Also

What is Probiotec Ltd's Interest Income Expense?
Interest Income Expense
-6m AUD

Based on the financial report for Dec 31, 2023, Probiotec Ltd's Interest Income Expense amounts to -6m AUD.

What is Probiotec Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-15%

Over the last year, the Interest Income Expense growth was -256%. The average annual Interest Income Expense growth rates for Probiotec Ltd have been -40% over the past three years , -37% over the past five years , and -15% over the past ten years .

Back to Top